Skip to content

Real-world multi-center cohort research project for early screening of lung cancer of health checkup population in zhejiang province

Real-world multi-center cohort research project for early screening of lung cancer of health checkup population in zhejiang province

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900027158
Enrollment
Unknown
Registered
2019-11-02
Start date
2018-11-01
Completion date
Unknown
Last updated
2019-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Index test:The&#32
risk&#32
assessment&#32
model&#32
of&#32
lung&#32
cancer&#32
for&#32
population.

Sponsors

The First Affiliated Hospital, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. aged 18-75 years; 2. at least one of the following risk factors should be combined: (1) smoking 20 packages year, including those who used to smoke, but quit less than 15 years; (2) passive smokers;(note: long-term passive smoking refers to the continuous smoke >= 0.5h/d for 5 years when there are smokers in the family or the same room); (3) occupational exposure history (asbestos, beryllium, uranium, radon and other contacts); (4) have a family genetic history of malignant tumors or a family history of lung cancer; (5) have a history of COPD, diffuse pulmonary fibrosis, tuberculosis, chronic pneumonia, asthma and other diseases.

Exclusion criteria

Exclusion criteria: 1. Serum samples with severe hemolysis, jaundice and hyperlipidemia; 2. Pregnant or lactating women; 3. Treatment or diagnosis of any cancer in five years. 4. The subjects had poor compliance and were not willing to receive lung cancer screening. 5. Patients with a history of organ transplantation or long-term use of immunosuppressive agents or people with HIV 6. Suffering from an autoimmune disease. 7. Having a history of surgery within one year (except biopsy); 8. Other situations not appropriate to participate judged by the researchers.

Design outcomes

Primary

MeasureTime frame
serum test of autoantibodies;LDCT;SEN, SPE, ACC, AUC of ROC;

Secondary

MeasureTime frame
tumor antigen biomarker;

Countries

China

Contacts

Public ContactZhong Liu

The First Affiliated Hospital, Zhejiang University

liuzhongzheyi121@163.com+86 13957104885

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026